Fennec Pharmaceuticals (FENC) Q2 2026: 78% Revenue Surge Highlights Commercial Expansion and Clinical Momentum

August 11, 2026 | By EarningsIQ Research

Fennec Pharmaceuticals delivered a robust 78% year-over-year revenue increase in Q2 2026, fueled by expanded commercial reach and growing clinical validation of PEDMARC, its flagship product. The company’s strategic disease awareness campaign and increased patient enrollments underpin sustained momentum entering Q3. Execution of integrated commercial and medical affairs initiatives positions Fennec for continued growth and potential label expansion.

Summary

• Commercial Expansion Drives Growth: Broadening prescriber base and sales force enhancements boost patient enrollments and demand.
• Clinical Evidence Fuels Adoption: Investigator-Sponsored Studies and medical affairs efforts deepen confidence in PEDMARC’s role in hearing loss prevention.
• Strategic Awareness Campaigns Amplify Reach: Innovative initiatives like Indy's Nuts and ASCO engagement broaden disease and product awareness beyond traditional channels.

Business Overview

Fennec Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing PEDMARC, a treatment designed to prevent cisplatin-induced hearing loss (CIO) in pediatric and adolescent and young adult (AYA) cancer patients. The company generates revenue primarily through sales of PEDMARC and supports growth through clinical development, medical affairs, and targeted commercial initiatives. Its major segments include commercial sales, clinical evidence generation, and strategic disease awareness programs.

Performance Analysis

In Q2 2026, Fennec reported net product sales of $17.1 million, marking a significant 78% increase compared to $9.7 million in Q2 2025. This growth was driven by expanded commercial reach, with the sales force increasing prescriber targets from 1,300 to approximately 5,000, resulting in a 280% increase in sales calls. Patient enrollments hit an all-time high, supported by the NCCN 2A recommendation for AYA patients and a growing preference for home infusion options, which accounted for over half of the business.

Operating expenses rose by $3.6 million year-over-year, mainly due to increased SG&A spending on marketing and commercial headcount expansion. Despite this, the company achieved a non-GAAP adjusted EBITDA of $2.8 million, a notable turnaround from a $1.2 million loss in the prior year. Cash and cash equivalents increased slightly to $41.2 million, reflecting solid cash flow management amid growth investments.

• Patient Enrollment and Demand Surge: Record patient infusions and new enrollments in Q2 and July underscore accelerating commercial traction.
• Balanced Academic and Community Penetration: Growth is well-distributed across academic centers and community oncology practices, supported by formulary wins.
• Operating Leverage Emerging: Fixed cost structure enables meaningful EBITDA improvement as revenue scales.

Overall, Fennec’s financial results reflect effective execution of its commercial expansion and clinical validation strategies, setting a foundation for sustained growth and profitability improvement.

Executive Commentary

Strategic Positioning

1. Commercial Scale and Reach Expansion

Fennec has significantly broadened its commercial footprint by increasing its prescriber target base nearly fourfold and expanding the sales force with experienced representatives. This has led to higher sales call volumes and penetration into previously underserved regions, contributing to record patient enrollments and infusions. The integration of commercial, medical affairs, and market access teams supports a coordinated approach to customer engagement and formulary placement, exemplified by recent wins in community oncology networks.

2. Clinical Evidence Generation and Label Expansion Potential

The company is advancing multiple Investigator-Sponsored Studies (ISTs) across tumor types and patient populations, including pediatric, AYA, head and neck, and gynecologic cancers. These studies aim to build a broader clinical evidence base for PEDMARC, which is critical for regulatory discussions and potential label expansions. The upcoming oral presentation of Phase 2-3 STS-J01 trial data in Japan at the SIOP 2026 Annual Meeting represents a key milestone in demonstrating PEDMARC’s pharmacokinetics and clinical profile.

3. Innovative Disease Awareness Campaigns

Fennec’s "Indy's Nuts" campaign at the Indianapolis 500 and its interactive ASCO booth have effectively raised awareness of testicular cancer and CIO prevention beyond traditional healthcare settings. These initiatives have generated strong engagement metrics and fostered meaningful dialogue with healthcare professionals and patient advocates, positioning PEDMARC as a leader in changing the standard of care.

4. Geographic and Market Expansion Efforts

The company is actively pursuing regulatory and commercial opportunities in Japan and broader Asia-Pacific, leveraging clinical data and ongoing discussions with potential partners. This measured approach aims to maximize long-term value and accelerate PEDMARC’s availability in new markets while ensuring strategic alignment with local stakeholders.

5. Lifecycle Management and Portfolio Growth

Fennec is exploring complementary oncology supportive care opportunities to leverage its expanded sales force and commercial infrastructure. While no definitive acquisitions or in-licensing deals have been announced, management remains open to adding products that align with PEDMARC’s commercial and clinical profile to sustain growth momentum.

Key Considerations

Q2 2026 results underscore the importance of Fennec’s multi-faceted growth strategy, combining commercial scale, clinical validation, and innovative awareness efforts. Investors should weigh the following:

• Commercial Execution: The rapid ramp of new sales representatives and expansion of prescriber targets are key drivers but require continued productivity gains to sustain growth.
• Clinical Evidence Impact: Success of ISTs and guideline updates will be pivotal for broader PEDMARC adoption and potential label expansion.
• Market Diversification: Balanced growth across academic and community settings reduces concentration risk and supports broader patient access.
• Operational Leverage: Fixed cost base offers margin expansion potential as revenue scales, but increased marketing and headcount investments require monitoring.
• International Expansion: Japan and Asia-Pacific opportunities represent significant upside but depend on regulatory approvals and partnership execution.

Risks

Fennec faces risks including dependence on continued clinical trial success and regulatory approvals for label expansion, potential delays in investigator-sponsored study accruals, and competitive pressures in oncology supportive care. Execution risk in scaling the commercial organization and maintaining patient enrollment growth also remains. Additionally, regulatory and market dynamics in international expansion present uncertainties that could affect timing and returns.

Forward Outlook

For Q3 2026, management highlighted ongoing momentum with record patient enrollments and infusion completions continuing into July and early August. While formal revenue guidance is not provided, the company anticipates meaningful growth acceleration in the second half of the year driven by commercial execution and clinical progress.

• Expect continued sequential growth in product sales and patient enrollments.
• Anticipate further evidence generation milestones and potential guideline updates.

Management remains focused on EBITDA generation and cash flow positivity by year-end, supported by disciplined expense management and revenue growth.

Takeaways

Fennec Pharmaceuticals is demonstrating strong execution in scaling its commercial platform and advancing clinical validation for PEDMARC, driving significant revenue growth and operational leverage. The company’s innovative disease awareness campaigns and balanced penetration across academic and community oncology settings enhance market positioning. Investors should monitor clinical study progress, guideline developments, and international expansion efforts as key catalysts for sustained growth.

• Commercial Momentum: Expanded sales force and prescriber targeting have materially increased patient enrollments, underpinning record demand and revenue growth.
• Clinical Validation as Growth Engine: Ongoing ISTs and upcoming data presentations are critical to broadening PEDMARC’s label and adoption, with potential to unlock new patient populations.
• Strategic Awareness Initiatives: Campaigns like Indy's Nuts and ASCO engagement extend reach beyond traditional channels, fostering brand leadership and clinical conversations.

Conclusion

Fennec Pharmaceuticals’ Q2 2026 results reflect a company successfully executing on its growth strategy by scaling commercial operations, advancing clinical evidence, and innovating in disease awareness. The momentum carried into Q3, combined with a strong financial foundation, positions Fennec well for continued expansion and value creation in the evolving oncology supportive care market.

Industry Read-Through

Fennec’s experience highlights the critical role of integrated commercial and medical affairs strategies in driving adoption of niche oncology supportive care products. The emphasis on disease awareness campaigns beyond traditional healthcare settings signals a broader industry trend toward patient and community engagement to address unmet needs. Additionally, the balanced growth across academic and community oncology practices underscores the importance of multi-channel penetration for sustained commercial success. Emerging data from investigator-sponsored studies and guideline updates remain key levers for expanding market opportunity in this specialized segment, offering valuable lessons for other companies targeting supportive care in oncology.

FENC Healthcare Biopharmaceuticals Oncology Commercial Expansion Clinical Evidence Disease Awareness Patient Enrollment